Akero Therapeutics has hit a home run, reporting statistically significant results in two key 96-week metabolic ...

With GLP-1-related drugs having won the race to weight loss approval, attention at many obesity-focused biopharmas has turned to the trickier task of finding a way to lose fat while retaining muscl | ...

Despite making up a sizable chunk of entry-level employees at the biggest U.S. biopharmas, the share of east Asian Americans drops dramatically as you move up the ranks. | Despite making up a sizable ...

Japan’s Nippon Shinyaku is continuing to scoop up the international rights to some intriguing drugs, this time penning a $686 ...

British pharma giant GSK is heading back to school, pledging up to 50 million pounds sterling (about $62.4 million) to work ...

With the full-scale launch of its latest surgical robot set for the middle of this year, Intuitive Surgical said that, to ...

After what many considered a “slow” year for IPOs, January has ushered in a string of biotechs filing to go public. But 2024 ...

Rare disease drug maker Pharming Group is calling off the search for a CEO successor to longtime chief Sijmen de Vries after ...

Novo Nordisk has reported 22% weight loss in people who received weekly amycretin injections for 36 weeks, triggering an 11% ...

The buzz around biotech IPOs is continuing through January, with clinical-stage metabolic company Aardvark Therapeutics ...

Flagship Pioneering is leveraging its year-old London outpost to forge new research collaborations across the pond. | ...

AstraZeneca is expanding its boot print in Canada with a $570 million investment designed to create 700 jobs. | AstraZeneca is expanding its boot print in Canada with a $570 million investment ...